How Medicaid Expansion Changed Opioid Treatment Access

When the Affordable Care Act (ACA) passed in 2010, its Medicaid expansion provision wasn't expected to become one of the most significant policy tools in addressing the opioid crisis. Yet by 2026, the data tells a clear story: states that expanded Medicaid saw dramatic increases in treatment enrollment for opioid use disorder (OUD), while non-expansion states continue to struggle with coverage gaps that leave thousands without access to life-saving medication like Suboxone (buprenorphine).

For people navigating OUD in expansion states like Ohio, Virginia, and Pennsylvania, Medicaid expansion has fundamentally changed what's possible. But the policy landscape remains uneven across the country, and even in expansion states, significant barriers persist for vulnerable populations.

Understanding how Medicaid expansion works—and where it still falls short—helps explain why treatment access varies so dramatically depending on where you live.

What Medicaid Expansion Actually Changed for OUD Treatment

Before the ACA, Medicaid eligibility was primarily limited to specific populations: children, pregnant women, parents with dependent children, elderly adults, and people with disabilities. Most low-income adults without children—a group with high rates of opioid use disorder—were simply ineligible, regardless of how little they earned.

The ACA's Medicaid expansion changed that by extending coverage to all adults with incomes up to 138% of the federal poverty level (about $20,780 for an individual in 2026). This opened the door for millions of adults who had been locked out of coverage.

For OUD treatment specifically, expansion states saw:

• Increased enrollment in medication-assisted treatment (MAT): Studies show a 70-100% increase in buprenorphine prescriptions in expansion states compared to non-expansion states in the years following expansion.
• Reduced uninsured rates among people with OUD: The uninsured rate among non-elderly adults with OUD dropped from 37% pre-expansion to 18% post-expansion in states that expanded.
• Better continuity of care: Medicaid coverage allows for ongoing treatment rather than episodic emergency care, enabling people to stay on medications like Suboxone long-term.
• Coverage for counseling and support services: Expansion plans typically cover behavioral health services alongside medication, supporting comprehensive recovery.

The impact wasn't just statistical. For individuals, expansion meant the difference between no treatment and consistent access to Suboxone treatment that could be sustained over months or years.

The Timeline: How Ohio, Virginia, and Pennsylvania Expanded Coverage

Each state's expansion story reflects different political contexts and implementation challenges, but all three states where Grata Health operates have expanded Medicaid—though on very different timelines.

Pennsylvania: Early Adopter (2015)

Pennsylvania expanded Medicaid on January 1, 2015, under a modified plan called "Healthy Pennsylvania." The expansion immediately extended coverage to an estimated 600,000 adults. For OUD treatment, this meant:

• Comprehensive coverage for buprenorphine medications including Suboxone
• Access to both office-based treatment and telehealth services
• Coverage for counseling and case management
• Same-day enrollment for people entering treatment

Pennsylvania's early expansion gave the state a head start in building infrastructure for OUD treatment. By 2018, the state had one of the highest rates of Medicaid-covered buprenorphine treatment in the country. Pennsylvania Medicaid now covers treatment through providers like Grata Health with minimal barriers.

Ohio: Expansion Under Republican Leadership (2014)

Ohio became one of the first Republican-led states to expand Medicaid, with coverage beginning January 1, 2014. Governor John Kasich championed expansion despite opposition from his own party, arguing that coverage for addiction treatment was both a moral imperative and fiscally responsible.

Ohio's expansion covered approximately 700,000 adults and had an immediate impact on OUD treatment access:

• Buprenorphine prescriptions covered by Medicaid increased 900% between 2013 and 2017
• The percentage of OUD treatment admissions paid by Medicaid rose from 28% to 45%
• Telehealth coverage expanded, making treatment accessible in rural counties

Ohio Medicaid has become particularly robust in covering telehealth addiction treatment, allowing providers like Grata Health to serve patients across the state, from Cleveland to Cincinnati to small rural communities.

Virginia: The Holdout That Changed (2019)

Virginia resisted Medicaid expansion for years despite bipartisan legislative support, with Republican governors blocking expansion until 2019. When expansion finally passed, it came with explicit provisions targeting the opioid crisis:

• Coverage began January 1, 2019, for adults earning up to 138% of the federal poverty level
• Specific carve-outs prioritizing substance use disorder treatment
• Expedited enrollment pathways for people in crisis
• Enhanced telehealth provisions for rural areas

Virginia's expansion covered approximately 400,000 adults in its first year. The impact on OUD treatment was swift: by the end of 2019, Medicaid-covered buprenorphine prescriptions had increased 150% compared to 2018. Virginia Medicaid now provides comprehensive coverage for Suboxone treatment, making care accessible in cities like Richmond, Virginia Beach, and Norfolk.

The Data: What Changed After Expansion

The real-world impact of Medicaid expansion on OUD treatment access goes beyond enrollment numbers. Research shows measurable improvements in health outcomes, overdose prevention, and treatment retention.

Treatment Enrollment Surged

A 2023 study in Health Affairs found that expansion states saw:

• 27% increase in OUD treatment admissions overall
• 185% increase in Medicaid-financed treatment admissions
• 12% reduction in self-pay or uninsured treatment admissions (suggesting more people could afford care)
• 40% increase in buprenorphine prescriptions per capita

In Ohio specifically, the number of people receiving Medicaid-covered buprenorphine treatment increased from 18,000 in 2013 to over 75,000 in 2020—a more than four-fold increase.

Overdose Deaths Declined (But Not Everywhere)

Expansion states saw slower growth in opioid overdose deaths compared to non-expansion states, particularly in the early years of expansion (2014-2016). A national study found that expansion states had 6% fewer opioid overdose deaths per capita than non-expansion states.

However, the fentanyl crisis complicated this picture. After 2016, as fentanyl contamination became widespread, even expansion states saw rising overdose deaths. The difference was in survival: expansion states had better access to naloxone, emergency response, and post-overdose treatment engagement.

Continuity of Care Improved

Before expansion, people without insurance often cycled through detox facilities, emergency rooms, and short-term treatment episodes without long-term medication support. Expansion enabled:

• Longer average treatment duration (from 3.2 months pre-expansion to 8.7 months post-expansion in one study)
• Higher rates of treatment retention at 6 and 12 months
• Better integration of medical and behavioral health care
• Reduced relapse rates due to continuous medication access

For patients on Suboxone, this continuity is critical. Treatment works best when people can stay on medication as long as they need it—months or years—without insurance disruptions forcing them off.

Who Still Falls Through the Coverage Gaps

Despite its impact, Medicaid expansion hasn't solved coverage problems for everyone with OUD. Significant gaps remain, even in expansion states.

The Documentation Barrier

Medicaid enrollment requires proof of identity, income, and residency—documents that people experiencing housing instability, recent incarceration, or crisis may not have readily available. While emergency Medicaid can sometimes bridge the gap, it doesn't cover ongoing treatment.

This hits particularly hard in communities where OUD intersects with homelessness. A person living unhoused in Philadelphia or Columbus may technically qualify for Medicaid but struggle to complete enrollment without a stable address or ID.

Immigration Status Exclusions

Undocumented immigrants are categorically excluded from Medicaid expansion, regardless of income or medical need. Legal immigrants must generally wait five years after obtaining legal status before qualifying. This leaves thousands of people with OUD—including parents and workers who've lived in the U.S. for years—without access to treatment.

The Criminal Justice Gap

Many states, including Pennsylvania and Virginia, automatically suspend or terminate Medicaid coverage when someone is incarcerated. This means people entering jail or prison lose coverage, and upon release, face re-enrollment barriers at a time when overdose risk is highest.

Ohio has implemented "suspension" rather than "termination," allowing faster re-activation upon release, but gaps still exist. People leaving incarceration often need treatment immediately, but may wait weeks for coverage to kick in—a dangerous window when treatment for fentanyl addiction is urgently needed.

Young Adults Aging Out of Coverage

Young adults who age out of foster care or family coverage at 21 or 26 can fall into gaps if they're not automatically enrolled in Medicaid. This population has high rates of OUD but low rates of health insurance literacy, leading to coverage lapses at a critical developmental period.

Grata Health works with patients across these situations, offering self-pay options when coverage gaps emerge while helping them navigate enrollment or appeals.

Ready to explore your Medicaid coverage options? See if you qualify for treatment with Grata Health.

The Non-Expansion States: A Stark Contrast

As of 2026, 10 states still have not expanded Medicaid under the ACA. The contrast in treatment access is striking.

In non-expansion states:

• Adults without children are generally ineligible for Medicaid regardless of income
• Uninsured rates among people with OUD remain above 35%
• Treatment capacity is limited, with long waiting lists at publicly funded programs
• Telehealth options are constrained by insurance barriers
• Overdose death rates have grown faster than in expansion states

A person earning $15,000 a year with OUD in a non-expansion state typically has no affordable treatment options. They earn too much for limited state programs but too little to afford marketplace insurance premiums. This creates a "coverage gap" where thousands of people simply go untreated.

The geographic divide means that treatment access depends heavily on which side of a state line you live on—a policy outcome that has very little to do with clinical need or effectiveness.

The Role of Federal Funding and State Flexibility

Medicaid expansion is funded primarily by the federal government, which covers 90% of costs for the expansion population (compared to 50-75% for traditional Medicaid populations, depending on the state). This generous federal match was designed to incentivize states to expand.

But states still have significant flexibility in how they structure coverage, creating variation even among expansion states:

Prior Authorization Requirements

Some states require prior authorization for Suboxone prescriptions, adding delays and administrative burden. Ohio and Virginia have relatively streamlined authorization processes, while Pennsylvania requires prior auth for certain formulations but not others.

Managed Care vs. Fee-for-Service

Most expansion states use managed care plans (like Anthem BCBS, Highmark, or CareSource) rather than traditional Medicaid. This can affect which providers are in-network and how quickly claims are paid.

Telehealth Coverage Rules

Expansion created the eligible population, but state telehealth rules determine whether patients can actually access remote treatment. All three expansion states where Grata operates have maintained strong telehealth coverage post-pandemic, making virtual Suboxone treatment widely available.

Work Requirements and Premium Contributions

Some states have tried to implement work requirements or premium payments for expansion populations, though courts have struck down many of these provisions. These added requirements can create barriers to enrollment or retention even when people technically qualify for coverage.

Current Policy Debates and Advocacy Efforts

Medicaid expansion remains politically contentious, and ongoing debates shape the future of treatment access.

Redetermination and the "Unwinding"

After pandemic-era continuous enrollment protections ended in 2023, millions of people lost Medicaid coverage during the "unwinding" process—not because they were ineligible, but due to administrative issues, missed paperwork, or incorrect data. States with robust renewal processes (like Pennsylvania) saw lower rates of inappropriate disenrollisement, while others saw widespread coverage losses.

Advocacy groups are pushing for:

• Automatic renewal using available data sources
• Extended renewal periods (12 months rather than quarterly checks)
• Text message and email notifications before termination
• Simplified recertification processes

Section 1115 Waivers for Reentry Populations

States are increasingly using Section 1115 Medicaid waivers to provide coverage during the 30 days before release from incarceration. California, Washington, and other states have implemented "reentry waiver" programs that allow Suboxone to be initiated before release, bridging the critical gap when overdose risk peaks.

Ohio, Pennsylvania, and Virginia are all exploring similar waivers. This would allow treatment to begin while people are still incarcerated, with seamless continuation post-release.

Expanding Beyond 138% FPL

Some advocates argue for raising the income ceiling above 138% of the federal poverty level, noting that people earning $25,000-$30,000 annually still struggle to afford marketplace insurance premiums. This would expand coverage to working adults in low-wage jobs who currently fall just above the cutoff.

Fixing the Immigration Coverage Gap

Several states have explored using state-only funds to cover undocumented immigrants for certain services, including addiction treatment. While federal Medicaid dollars can't be used for this population, state dollars can—though political and budgetary barriers remain significant.

What Medicaid Expansion Means for Patients Today

For someone seeking treatment in 2026, Medicaid expansion has fundamentally changed the landscape—but navigating coverage still requires understanding the system.

If you live in an expansion state and earn less than about $20,780/year (or about $35,630 for a family of three), you likely qualify for Medicaid that covers:

• Suboxone and other buprenorphine medications
• Intake appointments and ongoing visits
• Counseling and behavioral health services
• Lab work and drug testing
• Naloxone and overdose prevention supplies
• Telehealth visits

Grata Health accepts Medicaid in Virginia, Ohio, and Pennsylvania, including plans through Anthem BCBS, Highmark, CareSource, and other major managed care organizations.

If you're not sure about your coverage status, the enrollment process has become significantly more streamlined in recent years. Many people can enroll online, and some community health centers and treatment providers have "enrollment assisters" who can help complete applications on-site.

The Unfinished Work: Advocacy and Next Steps

Medicaid expansion was a game-changer for OUD treatment access, but the work is far from finished. The most pressing advocacy priorities include:

• Full nationwide expansion: Closing the coverage gap in the 10 non-expansion states would extend coverage to an estimated 1.8 million adults, many of whom need addiction treatment.
• Simplified enrollment and retention: Reducing administrative barriers so that people don't lose coverage due to paperwork issues during crises.
• **Justice-